This page is intended for members of the public.
Medical Information
If you have a medical information question or product quality concern regarding a Daiichi Sankyo product you can contact our Medical Information service on 0800 028 5122 or by email to medinfo@daiichi-sankyo.co.uk.
Please note: Pharmaceutical company Medical Information services cannot provide personal medical advice.
Side Effect Reporting
Side effects (adverse events) should be reported. The documents for some medicines also display an inverted black triangle symbol indicating that they are subject to additional monitoring to support the quick identification of new safety information.
If you are a patient and experience any side effects while taking a Daiichi Sankyo product, please talk to your doctor, pharmacist or nurse. You can also report side effects directly to the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help build the knowledge regarding the safety of the medicine.
If you are a health professional, adverse event reporting forms and information can be found at www.mhra.gov.uk/yellowcard (or search for MHRA Yellow Card in Google Play or Apple App store). Adverse events should also be reported to Daiichi Sankyo on 0800 028 5122 or by email to pharmacovigilance@daiichi-sankyo.co.uk
Products
| Product | Summary of Product Characteristics (SmPC) | Patient Information Leaflet (PIL) |
|---|---|---|
| Enhertu▼ (trastuzumab deruxtecan) | ||
| Lixiana (edoxaban tosilate) | ||
| Nilemdo▼ (bempedoic acid) | ||
| Nustendi▼ (bempedoic acid, ezetimibe) | ||
| Olmetec (olmesartan medoximil) | UK SmPC | UK PIL |
| Olmetec Plus 20 mg/12.5 mg & 20 mg/12.5 mg (olmesartan medoximil, hydrochlorothiazide) | UK SmPC | UK PIL |
| Olmetec Plus 40 mg/12.5 mg olmesartan medoximil, hydrochlorothiazide) | UK SmPC | UK PIL |
| Sevikar (olmesartan medoximil, amplodipine besilate) | UK SmPC | UK PIL |
| Sevikar HCT (olmesartan medoximil, amplodipine besilate, hydrochlorothiazide) | UK SmPC | UK PIL |
DSC/23/0089 April 2023
